Oral Chemotherapy Medications: The Need for a Nurse's Touch

Winkeljohn, Debra

doi:10.1188/07.cjon.793-796

Cited by 23 publications

(30 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14,25,44,81,82 Nurses who are strong patient advocates should also participate in adherence monitoring during the therapy. 83 If patients are ultimately accountable for adhering to their prescribed treatment, they can be supported through effective communication and partnership with their healthcare providers.Demonstrating the economic benefit of implementing adherence-improving programs in CML, along with the clinical benefits achieved with adherence, may be required to widely promote their adoption by the decision makers. …”

mentioning

confidence: 99%

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

et al. 2014

View full text Add to dashboard Cite

Correspondence: Lucien.Noens@uzgent.be BCR-ABL inhibitors for treating chronic myeloid leukemia in chronic phase have transformed a previously incurable malignancy into a manageable condition. However, suboptimal medication adherence has been observed with these agents affecting clinical outcomes and healthcare costs. In order to raise awareness of the problem of adherence, and before developing pragmatic strategies to enhance medication adherence, a deep understanding of the best approaches for measuring adherence in chronic myeloid leukemia patients and identifying non-adherence is required. A systematic literature review on the prevalence, measurement methods, consequences and risk factors for non-adherence to BCR-ABL inhibitors and adherence-enhancing interventions was performed and critically appraised. Of the 19 included articles, 9 were retrospective. Average adherence varied from 19% to almost 100% of the proportion of prescribed drug taken, but it was measured through various different methods and within different study groups. Suboptimal adherence was associated with a negative impact on both clinical and economic outcomes. There is a lack of supportive evidence demonstrating a difference in adherence across BCR-ABL inhibitors and even contradictory results between the 2 nd generation inhibitors. Drug-related adverse events and forgetfulness were common reasons for intentional and unintentional non-adherence, respectively, but further research is required to identify additional reasons behind non-adherence or patients at risk of non-adherence. Non-adherence in chronic myeloid leukemia patients treated with BCR-ABL inhibitors is common and associated with critical outcomes. However, this review highlights important existing gaps, reveals inconsistent definitions, and a lack of standardized methods for measuring adherence in chronic myeloid leukemia. All require further investigation. ABSTRACT © F e r r a t a S t o r t i F o u n d a t i o nAnalyses statement for systematic reviews. 16 Publication database (EMBASE, PubMed, and Cochrane Library) specific search terms consisted of both single and MeSH terms for the disease, adherence and BCR-ABL inhibitor therapy (Online Supplementary Table S1). The last search was conducted on December 20 th , 2011. Full-text references were provided for the eligible abstracts that were published after completion of the search process and the analyses. In addition, and due to the lack of existing evidence of adherence in CML, clinical and economic conference proceedings were also searched with a time limit of three years. Preliminary inclusion (or exclusion) of a specific study or conference abstract was based on review of the title and abstract by 2 independent reviewers against pre-specified criteria (Table 1). Final inclusion of the study was based on an in-depth review of the full manuscript. Multiple variables were extracted from the articles to answer study objectives (Online Supplementary Table S2). The analysis was descriptive only. Since abstracts in conference pr...

show abstract

mentioning

confidence: 99%

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Between the years 2005 and 2007, over a dozen new oral cancer chemotherapy agents had been approved by the US Food and Drug Administration, a trend that perhaps suggests many more such oral cancer agents will enter into clinical practice in the near future [3]. New agents in development are heterogenous.…”

Section: Introductionmentioning

confidence: 98%

Oral Cancer Chemotherapy: The Critical Interplay Between Patient Education and Patient Safety

Halfdanarson

Jatoi

2010

Curr Oncol Rep

View full text Add to dashboard Cite

Currently, 10% of cancer chemotherapy is prescribed to patients by means of an oral formulation, but, by 2013, this percentage is predicted to increase to 25%. Oral chemotherapy offers many advantages, including no need for sometimes painful intravenous access, no intravenous drug administration fees, more time at home for patients, and a greater sense of patient autonomy. However, oral cancer chemotherapy also poses challenges, many of which revolve around adherence and safety. These challenges are discussed here. There are few other circumstances in which patient education and the maintenance of institutional safety infrastructure play such an integral role in sustaining favorable cancer clinical outcomes.

show abstract

“…Viele 18 and Winkeljohn 19 both support the idea of compliance diaries in assisting compliance with oral cancer therapies. This also was suggested by 1 clinical pharmacist in this study.…”

Section: -17mentioning

confidence: 99%

Pharmacists' Role in Targeted Cancer Therapy in Australia and Implications for Pharmacy Education

Plevin

Ward

et al. 2010

American Journal of Pharmaceutical Education

View full text Add to dashboard Cite

Oral Chemotherapy Medications: The Need for a Nurse's Touch

Cited by 23 publications

References 16 publications

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

Oral Cancer Chemotherapy: The Critical Interplay Between Patient Education and Patient Safety

Pharmacists' Role in Targeted Cancer Therapy in Australia and Implications for Pharmacy Education

Contact Info

Product

Resources

About